Citations (97)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Yanyun Xu, Xin Zhong, Xiongwen Zhang, Wei Lv, Jiahui Yu, Yi Xiao, Shiyuan Liu & Jin Huang. (2017) Preparation of intravenous injection nanoformulation via co-assemble between cholesterylated gemcitabine and cholesterylated mPEG: enhanced cellular uptake and intracellular drug controlled release. Journal of Microencapsulation 34:2, pages 185-194.
Read now
Read now
Malyn M Asuncion Valenzuela, Imilce Castro, Amber Gonda, Carlos J Diaz Osterman, Jessica M Jutzy, Jonathan R Aspe, Salma Khan, Jonathan W Neidigh & Nathan R Wall. (2015) Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase. OncoTargets and Therapy 8, pages 495-507.
Read now
Read now
Xinzhe Yu, Yang Di, Chao Xie, Yunlong Song, Hang He, Hengchao Li, Xinming Pu, Weiyue Lu, Deliang Fu & Chen Jin. (2015) An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. International Journal of Nanomedicine 10, pages 6825-6834.
Read now
Read now
Derek Lamont West, Sarah B White, Zhouli Zhang, Andrew C Larson & Reed A Omary. (2014) Assessment and optimization of electroporation-assisted tumoral nanoparticle uptake in a nude mouse model of pancreatic ductal adenocarcinoma. International Journal of Nanomedicine 9, pages 4169-4176.
Read now
Read now
Daniel Ansari, Bobby Tingstedt & Roland Andersson. (2013) Pancreatic cancer – cost for overtreatment with gemcitabine. Acta Oncologica 52:6, pages 1146-1151.
Read now
Read now
Krissi Danielsson, Daniel Ansari & Roland Andersson. (2013) Personalizing Pancreatic Cancer Medicine: What are the Challenges?. Personalized Medicine 10:1, pages 45-59.
Read now
Read now
Jiang Long, Yuqing Zhang, Xianjun Yu, Jingxuan Yang, Drake G LeBrun, Changyi Chen, Qizhi Yao & Min Li. (2011) Overcoming drug resistance in pancreatic cancer. Expert Opinion on Therapeutic Targets 15:7, pages 817-828.
Read now
Read now
Lars Aabakken. (2009) This month in the Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology 44:7, pages 772-773.
Read now
Read now
Marika A. Frańczak, Claudine van der Sande, Elisa Giovannetti & Godefridus J. Peters. Effects of nucleoside analogues, lipophilic prodrugs and elaidic acids on core signaling pathways in cancer cells. Nucleosides, Nucleotides & Nucleic Acids 0:0, pages 1-11.
Read now
Read now
Articles from other publishers (88)
Fei-Fei Huang, Wen-Hui Cui, Lan-Yue Ma, Qi Chen & Yang Liu. (2023) Crosstalk of nervous and immune systems in pancreatic cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Tiantian Cui, Sergio Corrales-Guerrero, Veronica Castro-Aceituno, Sindhu Nair, Daniel C. Maneval, Curtis Monnig, Patrick Kearney, Sam Ellis, Nicholas Raheja, Neil Raheja & Terence M. Williams. (2023) JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis. Molecular Therapy - Oncolytics 30, pages 181-192.
Crossref
Crossref
Yuying Tan, Haonan Lin & Ji-Xin Cheng. (2023) Profiling single cancer cell metabolism via high-content SRS imaging with chemical sparsity. Science Advances 9:33.
Crossref
Crossref
Andriana Inkoom, Nkafu Bechem Ndemazie, Taylor Smith, Esther Frimpong, Raviteja Bulusu, Rosemary Poku, Xue Zhu, Bo Han, Jose Trevino & Edward Agyare. (2023) Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer 23:1.
Crossref
Crossref
Adrianne L. Jenner, Wayne Kelly, Michael Dallaston, Robyn Araujo, Isobelle Parfitt, Dominic Steinitz, Pantea Pooladvand, Peter S. Kim, Samantha J. Wade & Kara L. Vine. (2023) Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLOS Computational Biology 19:1, pages e1010104.
Crossref
Crossref
Zhenchong Li, Zuyi Ma, Qi Zhou, Shujie Wang, Qian Yan, Hongkai Zhuang, Zixuan Zhou, Chunsheng Liu, Zhongshi Wu, Jinglin Zhao, Shanzhou Huang, Chuanzhao Zhang & Baohua Hou. (2022) Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of pancreatic cancer. Heliyon 8:11, pages e11321.
Crossref
Crossref
Hui Shan Liew, Chun-Wai Mai, Mohd Zulkefeli, Thiagarajan Madheswaran, Lik Voon Kiew, Lesley Jia Wei Pua, Ling Wei Hii, Wei Meng Lim & May Lee Low. (2022) Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy. Frontiers in Pharmacology 13.
Crossref
Crossref
Marina Roy-Luzarraga, Louise E. Reynolds, Beatriz de Luxán-Delgado, Oscar Maiques, Laura Wisniewski, Emma Newport, Vinothini Rajeeve, Rebecca J.G. Drake, Jesús Gómez-Escudero, Frances M. Richards, Céline Weller, Christof Dormann, Ya-Ming Meng, Peter B. Vermeulen, Dieter Saur, Victoria Sanz-Moreno, Ping-Pui Wong, Cyrill Géraud, Pedro R. Cutillas & Kairbaan Hodivala-Dilke. (2022) Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment. Cancer Research 82:10, pages 1909-1925.
Crossref
Crossref
Sian Chen, Chenbin Chen, Yuanbo Hu, Gendi Song & Xian Shen. (2021) The diverse roles of circular RNAs in pancreatic cancer. Pharmacology & Therapeutics 226, pages 107869.
Crossref
Crossref
Ahmad Hamad, Zachary J Brown, Aslam M Ejaz, Mary Dillhoff & Jordan M Cloyd. (2021) Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. World Journal of Gastroenterology 27:27, pages 4383-4394.
Crossref
Crossref
Takeshi Matsumoto, Takashi Komori, Yuta Yoshino, Tadaaki Ioroi, Tsukasa Kitahashi, Hiromu Kitahara, Kohei Ono, Tamami Higuchi, Masayo Sakabe, Hiroshi Kori, Masahiro Kano, Ritsuko Hori, Yukio Kato & Shinji Hagiwara. (2021) A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models. Pharmaceutical Research 38:6, pages 1093-1106.
Crossref
Crossref
Bence Nagy, Angela Lamarca, Mairéad G. McNamara, Richard A. Hubner & Juan W. Valle. 2021. Textbook of Pancreatic Cancer. Textbook of Pancreatic Cancer
681
696
.
Andriana Inkoom, Nkafu Ndemazie, Kevin Affram, Taylor Smith, Xue Zhu, Patrick Underwood, Sunil Krishnan, Edward Ofori, Bo Han, Jose Trevino & Edward Agyare. (2020) Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models. International Journal of Pharmaceutics: X 2, pages 100056.
Crossref
Crossref
Fadia Attia, Sara Fathy, Maha Anani, Adel Hassan, Fawzy Attia, Gehan Ibrahim & Mona Elazab. (2020) Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. Journal of Clinical Laboratory Analysis 34:11.
Crossref
Crossref
Ying-Jie Sun, Li Liu & Liang Cheng. (2020)
Regioselective synthesis and anticancer evaluation of H
2
O
2
-activable nucleosides
. Chemical Communications 56:48, pages 6484-6487.
Crossref
Crossref
Xiaolu Wei, Jing He, Bo Gao, Lingyu Han, Yingqiu Mao, Haiyu Zhao, Nan Si, Hongjie Wang, Jian Yang & Baolin Bian. (2020) Hellebrigenin anti-pancreatic cancer effects based on apoptosis and autophage. PeerJ 8, pages e9011.
Crossref
Crossref
Xiaolu Wei, Jian Yang, Yingqiu MaoHaiyu Zhao, Nan Si, Hongjie Wang & Baolin Bian. (2020) Arenobufagin Inhibits the Phosphatidylinositol 3-kinase/Protein Kinase B/Mammalian Target of Rapamycin Pathway and Induces Apoptosis and Autophagy in Pancreatic Cancer Cells. Pancreas 49:2, pages 261-272.
Crossref
Crossref
Lucie Jiraskova, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud & Lukas Cerveny. (2019) Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?. Cancers 11:11, pages 1621.
Crossref
Crossref
Hehe Li, Zhengle Zhang, Chenggang Gao, Shihong Wu, Qingke Duan, Heshui Wu, Chunyou Wang, Qiang Shen & Tao Yin. (2019) Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells. Cell & Bioscience 9:1.
Crossref
Crossref
Carla Serri, Vincenzo Quagliariello, Rosario Vincenzo Iaffaioli, Sabato Fusco, Gerardo Botti, Laura Mayol & Marco Biondi. (2018) Combination therapy for the treatment of pancreatic cancer through hyaluronic acid‐decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study. Journal of Cellular Physiology 234:4, pages 4959-4969.
Crossref
Crossref
Ming-Chuan Hsu, Mei-Ren Pan, Pei-Yi Chu, Ya-Li Tsai, Chia-Hua Tsai, Yan-Shen Shan, Li-Tzong Chen & Wen-Chun Hung. (2018) Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression. Cancers 11:1, pages 8.
Crossref
Crossref
Konstantinos Kamposioras, Chrysiida Tsimplouli, Caroline Verbeke, Alan Anthoney, Argyro Daoukopoulou, Christos Papandreou, Nikolaos Sakellaridis, George Vassilopoulos, Spyros Potamianos, Vasiliki Liakouli, Gemma Migneco, Francesco Del Galdo & Konstantinos Dimas. (2018) Silencing of caveolin-1 in fibroblasts as opposed to epithelial tumor cells results in increased tumor growth rate and chemoresistance in a human pancreatic cancer model. International Journal of Oncology.
Crossref
Crossref
Deepanshi Dhar, Gagan Deep, Sushil Kumar, Michael F. Wempe, Komal Raina, Chapla Agarwal & Rajesh Agarwal. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Molecular Carcinogenesis 57:9, pages 1166-1180.
Crossref
Crossref
Manju Kanamala, Brian D. Palmer, Hamidreza Ghandehari, William R. Wilson & Zimei Wu. (2018) PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation. Pharmaceutical Research 35:8.
Crossref
Crossref
Yedong Wang, Yuan Li, Jia Lu, Huixin Qi, Isabel Cheng & Hongjian Zhang. (2018) Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro. Molecules 23:5, pages 1195.
Crossref
Crossref
Xiao Zhao, Xiuchao Wang, Wei Sun, Keman Cheng, Hao Qin, Xuexiang Han, Yu Lin, Yongwei Wang, Jiayan Lang, Ruifang Zhao, Xiaowei Zheng, Ying Zhao, Jian shi, Jihui Hao, Qing Robert Miao, Guangjun Nie & He Ren. (2018) Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Biomaterials 158, pages 44-55.
Crossref
Crossref
Chen Liang, Si Shi, Qingcai Meng, Dingkong Liang, Shunrong Ji, Bo Zhang, Yi Qin, Jin Xu, Quanxing Ni & Xianjun Yu. (2017) Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. Cellular and Molecular Life Sciences 75:6, pages 1001-1012.
Crossref
Crossref
Mohd Omar F. Sikder, Shengping Yang, Vadivel Ganapathy & Yangzom D. Bhutia. (2017) The Na+/Cl−-Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis. The AAPS Journal 20:1.
Crossref
Crossref
F. Joubert & G. Pasparakis. (2018) Hierarchically designed hybrid nanoparticles for combinational photochemotherapy against a pancreatic cancer cell line. Journal of Materials Chemistry B 6:7, pages 1095-1104.
Crossref
Crossref
Sandeep Kumar, Joseph R. Inigo, Rahul Kumar, Ajay K. Chaudhary, Jordan O'Malley, Srimmitha Balachandar, Jianmin Wang, Kristopher Attwood, Neelu Yadav, Steven Hochwald, Xinjiang Wang & Dhyan Chandra. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Letters 413, pages 82-93.
Crossref
Crossref
Yassar M. Hashim, Suwanna Vangveravong, Narendra V. Sankpal, Pratibha S. Binder, Jingxia Liu, S. Peter Goedegebuure, Robert H. Mach, Dirk Spitzer & William G. Hawkins. (2017) The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. Journal of Experimental & Clinical Cancer Research 36:1.
Crossref
Crossref
Manoj Amrutkar & Ivar Gladhaug. (2017) Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers 9:12, pages 157.
Crossref
Crossref
Oana Ursu, Sara J. C. Gosline, Neil Beeharry, Lauren Fink, Vikram Bhattacharjee, Shao-shan Carol Huang, Yan Zhou, Tim Yen & Ernest Fraenkel. (2017) Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLOS ONE 12:10, pages e0185650.
Crossref
Crossref
Li Wang, Ping Dong, Weiguo Wang, Mingquan Huang & Bole Tian. (2017) Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem‑like cells via induction of lncRNA HOTAIR. Experimental and Therapeutic Medicine.
Crossref
Crossref
Ahmed Abu-Fayyad & Sami Nazzal. (2017) Synthesis, physiochemical characterization, and in vitro antitumor activity of the amide and pH cleavable hydrazone conjugates of γ-tocotrienol isomer of vitamin E with methoxy-poly(ethylene) glycol. International Journal of Pharmaceutics 529:1-2, pages 75-86.
Crossref
Crossref
Ahmed Abu-Fayyad & Sami Nazzal. (2017) Gemcitabine-vitamin E conjugates: Synthesis, characterization, entrapment into nanoemulsions, and in-vitro deamination and antitumor activity. International Journal of Pharmaceutics 528:1-2, pages 463-470.
Crossref
Crossref
Giuseppe Aprile, Francesca V. Negri, Francesco Giuliani, Elisa De Carlo, Davide Melisi, Francesca Simionato, Nicola Silvestris, Oronzo Brunetti, Francesco Leone, Donatella Marino, Daniele Santini, Emanuela Dell’Aquila, Tea Zeppola, Marco Puzzoni & Mario Scartozzi. (2017) Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology 115, pages 1-12.
Crossref
Crossref
Fanny Joubert, Liam Martin, Sébastien Perrier & George Pasparakis. (2017) Development of a Gemcitabine-Polymer Conjugate with Prolonged Cytotoxicity against a Pancreatic Cancer Cell Line. ACS Macro Letters 6:5, pages 535-540.
Crossref
Crossref
Xiaoyu Yang, Yi Xu, Tao Wang, Dan Shu, Peixuan Guo, Keith Miskimins & Steven Y. Qian. (2017) Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells. Redox Biology 11, pages 653-662.
Crossref
Crossref
Antonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, Ruth Vera, Vega Iranzo, Inmaculada Ales, Sara Arévalo, Aleydis Pisa, Marta Martín, Antonieta Salud, Esther Falcó, Alberto Sáenz, José Luis Manzano Mozo, Gema Pulido, Joaquina Martínez Galán, Roberto Pazo-Cid, Fernando Rivera, Teresa García García, Olbia Serra, Eva Ma Fernández Parra, Alicia Hurtado, Ma José Gómez Reina, Luis Jesús López Gomez, Esther Martínez Ortega, Manuel Benavides & Enrique Aranda. (2017) Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. European Journal of Cancer 75, pages 73-82.
Crossref
Crossref
Justine M. Grixti, Steve O'Hagan, Philip J. Day & Douglas B. Kell. (2017) Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. Frontiers in Pharmacology 8.
Crossref
Crossref
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione & Stefano Fanti. 2017. Nuclear Oncology. Nuclear Oncology
749
775
.
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione & Stefano Fanti. 2017. Nuclear Oncology. Nuclear Oncology
1
27
.
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione & Stefano Fanti. 2017. Nuclear Oncology. Nuclear Oncology
1
27
.
V Coothankandaswamy, S Cao, Y Xu, P D Prasad, P K Singh, C P Reynolds, S Yang, J Ogura, V Ganapathy & Y D Bhutia. (2016) Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. British Journal of Pharmacology 173:23, pages 3292-3306.
Crossref
Crossref
Huixin Qi, Jia Lu, Jiajun Li, Meiyu Wang, Yunting Xu, Yedong Wang & Hongjian Zhang. (2016) Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation. Journal of Pharmaceutical Sciences 105:9, pages 2966-2973.
Crossref
Crossref
Xiaoyu Yang, Yi Xu, Amanda Brooks, Bin Guo, Keith W. Miskimins & Steven Y. Qian. (2016) Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs. Free Radical Biology and Medicine 97, pages 342-350.
Crossref
Crossref
Jie Xie, Zhong-Hua Tao, Jiang Zhao, Ting Li, Zheng-Hua Wu, Jin-Feng Zhang, Jian Zhang & Xi-Chun Hu. (2016) Glucose regulated protein 78 (GRP78) inhibits apoptosis and attentinutes chemosensitivity of gemcitabine in breast cancer cell via AKT/mitochondrial apoptotic pathway. Biochemical and Biophysical Research Communications 474:3, pages 612-619.
Crossref
Crossref
Zhen-Hua Wu, Zhong-Hua Tao, Jian Zhang, Ting Li, Chen Ni, Jie Xie, Jin-Feng Zhang & Xi-Chun Hu. (2015) MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer. Tumor Biology 37:6, pages 7245-7254.
Crossref
Crossref
XUEFEI TIAN, NARAYAN SHIVAPURKAR, ZHENG WU, JIMMY J. HWANG, MICHAEL J. PISHVAIAN, LOUIS M. WEINER, LISA LEY, DAN ZHOU, XIULING ZHI, ANTON WELLSTEIN, JOHN L. MARSHALL & AIWU RUTH HE. (2016) Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters 11:3, pages 1645-1650.
Crossref
Crossref
Ingela Henoch, Ida Carlander, Maja Holm, Inger James, Elisabeth Kenne Sarenmalm, Carina Lundh Hagelin, Susanne Lind, Anna Sandgren & Joakim Öhlén. (2015) Palliative Care Research – A Systematic Review of foci, designs and methods of research conducted in Sweden between 2007 and 2012. Scandinavian Journal of Caring Sciences 30:1, pages 5-25.
Crossref
Crossref
Junjie Xiong, Kiran Altaf, Nengwen Ke, Yichao Wang, Jie Tang, Chunlu Tan, Ang Li, Hao Zhang, Du He & Xubao Liu. (2016) dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma. Medicine 95:10, pages e2936.
Crossref
Crossref
Yifan Lian, Zeling Cai, Huangbo Gong, Songling Xue, Dongdong Wu & Keming Wang. (2016) HOTTIP: a critical oncogenic long non-coding RNA in human cancers. Molecular BioSystems 12:11, pages 3247-3253.
Crossref
Crossref
Youssef W. Naguib, Dharmika Lansakara-P.Laura M. Lashinger, B. Leticia Rodriguez, Solange Valdes, Mengmeng Niu, Abdulaziz M. Aldayel, Lan Peng, Stephen D. Hursting & Zhengrong Cui. (2016) Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity. Neoplasia 18:1, pages 33-48.
Crossref
Crossref
Elena Tabacchi, Cristina Nanni, Irene Bossert, Anna Margherita Maffione & Stefano Fanti. 2016. Nuclear Oncology. Nuclear Oncology
1
27
.
Chen Liang, Zhen Wang, Ying-Yi Li, Bao-Hua Yu, Fei Zhang & Hong-Yu Li. (2015) miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells. Tumor Biology 36:12, pages 9395-9403.
Crossref
Crossref
Tomohiro Nakano, Yuriko Saiki, Chiharu Kudo, Akiyoshi Hirayama, Yasuhiko Mizuguchi, Sho Fujiwara, Tomoyoshi Soga, Makoto Sunamura, Nobutoshi Matsumura, Fuyuhiko Motoi, Michiaki Unno & Akira Horii. (2015) Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK. Biochemical and Biophysical Research Communications 464:4, pages 1084-1089.
Crossref
Crossref
M. Sinn, H. Riess, B.V. Sinn, J.M. Stieler, U. Pelzer, J.K. Striefler, H. Oettle, M. Bahra, C. Denkert, H. Bläker & P. Lohneis. (2015) Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial. European Journal of Cancer 51:12, pages 1546-1554.
Crossref
Crossref
Aiqun Xue, Sohel M. Julovi, Thomas J. Hugh, Jaswinder S. Samra, Matthew H.F. Wong, Anthony J. Gill, Christopher W. Toon & Ross C. Smith. (2015) A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. Pancreatology 15:4, pages 397-404.
Crossref
Crossref
Chen Liang, Xian-Jun Yu, Xiao-Zhong Guo, Meng-Hong Sun, Zhen Wang, Yao Song, Quan-Xing Ni, Hong-Yu Li, Naofumi Mukaida & Ying-Yi Li. (2015) MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget 6:16, pages 14440-14455.
Crossref
Crossref
Daniel Ansari, Adam Gustafsson & Roland Andersson. (2015) Update on the management of pancreatic cancer: Surgery is not enough. World Journal of Gastroenterology 21:11, pages 3157-3165.
Crossref
Crossref
Siwei Cao, Huoji Chen, Shijian Xiang, Junhui Hong, Lidong Weng, Hongxia Zhu & Qiang Liu. (2015) Anti-Cancer Effects and Mechanisms of Capsaicin in Chili Peppers. American Journal of Plant Sciences 06:19, pages 3075-3081.
Crossref
Crossref
Douglas B. Kell. (2015) What would be the observable consequences if phospholipid bilayer diffusion of drugs into cells is negligible?. Trends in Pharmacological Sciences 36:1, pages 15-21.
Crossref
Crossref
Xing-dong Xu, Lan Yang, Li-yun Zheng, Yan-yan Pan, Zhi-fei Cao, Zhi-qing Zhang, Quan-sheng Zhou, Bo Yang & Cong Cao. (2014) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer 14:1.
Crossref
Crossref
Douglas B. Kell & Stephen G. Oliver. (2014) How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Frontiers in Pharmacology 5.
Crossref
Crossref
Paola Lecca. (2014) Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms. Drug Discovery Today 19:2, pages 151-163.
Crossref
Crossref
Jeffrey M Sutton. (2014) Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World Journal of Gastroenterology 20:42, pages 15564.
Crossref
Crossref
Godefridus J. Peters, Kees Smid, Leonardo Vecchi, Ietje Kathmann, Dzjemma Sarkisjan, Richard J. Honeywell, Nienke Losekoot, Osnat Ohne, Aric Orbach, Eran Blaugrund, Lak Shin Jeong, Young Bok Lee, Chang-Ho Ahn & Deog Joong Kim. (2013) Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Investigational New Drugs 31:6, pages 1444-1457.
Crossref
Crossref
O.E. Rahma, A. Duffy, D.J. Liewehr, S.M. Steinberg & T.F. Greten. (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of Oncology 24:8, pages 1972-1979.
Crossref
Crossref
Yihui Ma, Yumei Gu, Qiang Zhang, Yongqing Han, Shuangni Yu, Zhaohui Lu & Jie Chen. (2013)
Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth
In Vitro
and
In Vivo
. Molecular Cancer Therapeutics 12:3, pages 286-294.
Crossref
Crossref
Saijie Zhu, Piyanuch Wonganan, Dharmika S.P. Lansakara-P.Hannah L. O'Mary, Yue Li & Zhengrong Cui. (2013) The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. Biomaterials 34:9, pages 2327-2339.
Crossref
Crossref
Shengzhang Lin, Jianhong Zhang, Hui Chen, Kangjie Chen, Fuji Lai, Jiang Luo, Zhaohong Wang, Heqi Bu, Riyuan Zhang, Honghai Li & Hongfei Tong. (2013) Involvement of Endoplasmic Reticulum Stress in Capsaicin-Induced Apoptosis of Human Pancreatic Cancer Cells. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-12.
Crossref
Crossref
Paola Lecca. (2013) An integrative network inference approach to predict mechanisms of cancer chemoresistance. Integrative Biology 5:3, pages 458.
Crossref
Crossref
Ann H. Rosendahl, Chen Sun, DeQuan Wu & Roland Andersson. (2012) Polysaccharide-K (PSK) increases p21WAF/Cip1 and promotes apoptosis in pancreatic cancer cells. Pancreatology 12:6, pages 467-474.
Crossref
Crossref
Zuojia Liu, Dan Li, Wenjing Zhao, Xiliang Zheng, Jin Wang & Erkang Wang. (2012) A Potent Lead Induces Apoptosis in Pancreatic Cancer Cells. PLoS ONE 7:6, pages e37841.
Crossref
Crossref
Dharmika S.P. Lansakara-P.B. Leticia Rodriguez & Zhengrong Cui. (2012) Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. International Journal of Pharmaceutics 429:1-2, pages 123-134.
Crossref
Crossref
Si Shi, Wantong Yao, Jin Xu, Jiang Long, Chen Liu & Xianjun Yu. (2012) Combinational therapy: New hope for pancreatic cancer?. Cancer Letters 317:2, pages 127-135.
Crossref
Crossref
Mansi A. Parasramka & Smiti Vaid Gupta. (2012) Synergistic Effect of Garcinol and Curcumin on Antiproliferative and Apoptotic Activity in Pancreatic Cancer Cells. Journal of Oncology 2012, pages 1-8.
Crossref
Crossref
Woon-Gye Chung, Michael A. Sandoval, Brian R. Sloat, Dharmika S.P. Lansakara-P & Zhengrong Cui. (2012) Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. Journal of Controlled Release 157:1, pages 132-140.
Crossref
Crossref
Peer Joensson, Birgit Hotz, Heinz Johannes Buhr & Hubert G. Hotz. (2011) A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma. Langenbeck's Archives of Surgery 396:4, pages 535-541.
Crossref
Crossref
Yangzom D. Bhutia, Sau Wai Hung, Bhavi Patel, Dylan Lovin & Rajgopal Govindarajan. (2011) CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells. Cancer Research 71:5, pages 1825-1835.
Crossref
Crossref
Ren Nishio, Hiroyuki Tsuchiya, Toshihiro Yasui, Shizuka Matsuura, Keita Kanki, Akihiro Kurimasa, Ichiro Hisatome & Goshi Shiota. (2011) Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Science 102:3, pages 622-629.
Crossref
Crossref
Ioannis A Voutsadakis. (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World Journal of Gastrointestinal Oncology 3:11, pages 153.
Crossref
Crossref
AYAKO NAKAMURA, KAZUHIKO HAYASHI, GO NAKAJIMA, HIROTAKA KAMIKOZURU, RYUJI OKUYAMA, HIDEKAZU KURAMOCHI, TAKASHI HATORI & MASAKAZU YAMAMOTO. (2011) Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer. Experimental and Therapeutic Medicine 2:6, pages 1097-1103.
Crossref
Crossref
Wolfgang Hagmann, Ralf Faissner, Martina Schnölzer, Matthias Löhr & Ralf Jesnowski. (2010) Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma. Cancers 3:1, pages 106-125.
Crossref
Crossref
Xing J Zhang, Hua Ye, Cheng W Zeng, Bo He, Hua Zhang & Yue Q Chen. (2010) Dysregulation of miR-15a and miR-214 in human pancreatic cancer. Journal of Hematology & Oncology 3:1.
Crossref
Crossref
Yihui Ma, Shuangni Yu, Wugan Zhao, Zhaohui Lu & Jie Chen. (2010) miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Letters 298:2, pages 150-158.
Crossref
Crossref
Wolfgang Hagmann, Ralf Jesnowski & Johannes Matthias Löhr. (2010) Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells. Neoplasia 12:9, pages 740-747.
Crossref
Crossref